Evaluation of neutrophilia as a prognostic factor in dogs with multicentric lymphoma treated with a cyclophosphamide, doxorubicin, vincristine, and prednisone–based chemotherapy protocol

• DOI: 10.2460/javma.259.5.494
• Publication Date: 2021-08-13T18:05:03Z
• Authors: Sridhar Veluvolu; MacKenzie Pellin; Nathaniel Vos
• Keywords: Neutrophilia; Canine Lymphoma

Abstract OBJECTIVE To determine whether, in dogs with naïve multicentric lymphoma, neutrophilia at the time of initial diagnosis was associated progression-free survival (PFST) or overall response rate (ie, percentage a complete partial remission) and whether neutrophil-to-lymphocyte ratio PFST. ANIMALS 30 lymphoma (including 16 treated cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP]–based protocol) 37 historical control without CHOP-based protocol. PROCEDURES Medical records were reviewed, PFSTs responses documented. RESULTS Median PFST for protocol (70 days; range, 0 to 296 days) significantly shorter than that (184.5 23 503 days), (12/16 [75%]) lower (36/37 [97%]). However, when all study populations considered together, not CONCLUSIONS AND CLINICAL RELEVANCE Results suggested may suggest poorer prognosis lymphoma. Prospective investigation into role neutrophils peripheral circulation tumor microenvironment cancer-bearing patients is warranted.